Inhibikase Therapeutics, Inc.
$1.81
▼
-0.55%
2026-04-21 07:28:02
www.inhibikase.com
NCM: IKT
Explore Inhibikase Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$238.98 M
Current Price
$1.81
52W High / Low
$2.37 / $1.33
Stock P/E
—
Book Value
$1.02
Dividend Yield
—
ROCE
-30.85%
ROE
-36.04%
Face Value
—
EPS
$-0.49
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
35
Beta
0.86
Debt / Equity
0
Current Ratio
21.7
Quick Ratio
21.7
Forward P/E
-4.47
Price / Sales
—
Enterprise Value
$110.95 M
EV / EBITDA
-2.42
EV / Revenue
—
Rating
Strong Buy
Target Price
$5.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 2. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 3. | AIM ImmunoTech Inc. | $0.49 | — | $3.99 M | — | 2638.91% | 251.38% | $19.74 / $0.51 | $-3.19 |
| 4. | Inhibrx Biosciences, Inc. | $82.39 | — | $1.29 B | — | -119.83% | -1.98% | $94.56 / $10.84 | $0.55 |
| 5. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 6. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 7. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.13 M | -13.26 M | -11.19 M | -15.76 M | -12.93 M | — |
| Net Profit | -12.73 M | -11.93 M | -9.92 M | -13.68 M | -12.13 M | — |
| EPS in Rs | -0.1 | -0.09 | -0.08 | -0.1 | -0.09 | -0.65 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -53.35 M | -28.59 M | -20.09 M | -18.13 M |
| Net Profit | -48.26 M | -27.52 M | -19.03 M | -18.05 M |
| EPS in Rs | -0.37 | -0.21 | -0.14 | -0.14 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 181.2 M | 98.6 M | 14.51 M | 24.94 M |
| Total Liabilities | 8.3 M | 3.73 M | 3.53 M | 3.9 M |
| Equity | 172.9 M | 94.87 M | 10.98 M | 21.04 M |
| Current Assets | 180.11 M | 98.45 M | 14.21 M | 24.37 M |
| Current Liabilities | 8.3 M | 3.73 M | 3.44 M | 3.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -27.79 M | -19.15 M | -18.09 M | -17.35 M |
| Investing CF | 2.05 M | -37 M | 11.66 M | -16.01 M |
| Financing CF | 108.46 M | 103.48 M | 8.41 M | -0.2 M |
| Free CF | -28.24 M | -19.15 M | -18.1 M | -17.59 M |
| Capex | -0.45 M | — | -0.01 M | -0.24 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -44.62% | -5.4% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-30 | 1:0.166667 |